Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

avibactam

This page shows the latest avibactam news and features for those working in and with pharma, biotech and healthcare.

Allergan’s Avycaz breaks Gram-negative pneumonia antibiotic drought

Allergan’s Avycaz breaks Gram-negative pneumonia antibiotic drought

Originally developed by Actavis (which was acquired by Allergan in a $25bn deal in 2014), Avycaz combines established cephalosporin antibiotic ceftazidime with avibactam, a novel beta lactamase inhibitor that helps tackle

Latest news

  • Pfizer launches new antibiotic Zavicefta in UK and Germany Pfizer launches new antibiotic Zavicefta in UK and Germany

    The European Medicines Agency (EMA) cleared Zavicefta (ceftazidime and avibactam) for the treatment of complicated Gram-negative bacterial infections requiring hospitalisation last year.

  • AZ slims down again with sale of antibiotics to Pfizer AZ slims down again with sale of antibiotics to Pfizer

    The deal includes the approved antibiotics Merrem (meropenem), Zinforo (ceftaroline fosamil) and just-licensed Zavicefta (ceftazidime/avibactam), as well as two injectable antibiotic candidates - Allergan-partnered ATM-AVI (aztreonam/avibactam) and

  • AZ gets EU green light for new antibiotic Zavicefta AZ gets EU green light for new antibiotic Zavicefta

    The European Medicines Agency (EMA) cleared Zavicefta (ceftazidime and avibactam) for the treatment of serious Gram-negative bacterial infections requiring hospitalization. ... AZ and Actavis are also testing avibactam in combination with other beta

  • Merck starts pivotal trials of new antibiotic combination Merck starts pivotal trials of new antibiotic combination

    aeruginosa. AstraZeneca (AZ) recently secured CHMP backing in Europe for Zavicefta - which combines established cephalosporin antibiotic ceftazidime with new-generation beta lactamase inhibitor avibactam.

  • CHMP backs AZ's 'superbug' antibiotic product CHMP backs AZ's 'superbug' antibiotic product

    In the US, Actavis (now operating as Allergan) has been granted FDA approval for another combination of ceftazidime and avibactam, which is sold as Avycaz. ... Actavis gained rights to the combination after buying Forest Labs, which originally developed

More from news
Approximately 2 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Deal Watch August 2016 Deal Watch August 2016

    14, 000. AstraZeneca (UK) antibiotic business. Pfizer (US). Asset acquisition. EU approved ceftazidime-avibactam), marketed meropenem and ceftaroline fosamil and clinical development assets aztreonam-avibactam (ATM-AVI) and CXL.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Quick links

Infographics

Multimedia